Dr Reddys unveils generic version of Sapropterin Dihydrochloride Tablets in US
Hyderabad and Princeton: Dr. Reddy's Laboratories Ltd. has recently announced the launch of a generic version of Sapropterin Dihydrochloride Tablets, for Oral Use.
"We are pleased to launch this generic version of Sapropterin Dihydrochloride Tablets, for Oral Use, illustrating our continued commitment to bring affordable generic medicines to market for patients," says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy's Laboratories.
"At the same time, this product demonstrates that we are actively expanding the breadth of our portfolio with a treatment for a rare disease. We are pleased to provide financial support to patients by offering a co-pay card program for eligible patients, details will be available on our website."
Sapropterin dihydrochloride is a phenylalanine hydroxylase activator indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU).
Sapropterin dihydrochloride is to be used in conjunction with a Phe-restricted diet.
Dr. Reddy's Sapropterin Dihydrochloride Tablets, 100 mg are available in bottle count sizes of 120.
Read also: Dr Reddys seeks DCGI approval to conduct Sputnik V Phase-3 clinical trial
Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.
